Article Text

Download PDFPDF
Ambulatory palliative care and cancer symptom control: a systematic review and meta-analysis
  1. Rajvi Shah1,2,
  2. Rachel Everitt3,
  3. Dana Hince4,
  4. David Kissane2,5 and
  5. Natasha Michael2,5
  1. 1Department of Palliative Care, Campbelltown & Camden Hospitals, Campbelltown, New South Wales, Australia
  2. 2The University of Notre Dame Australia School of Medicine Sydney Campus, Darlinghurst, New South Wales, Australia
  3. 3Supportive and Palliative Care Department, Monash Health, Clayton, Victoria, Australia
  4. 4The Institute of Health Research, The University of Notre Dame Australia - Fremantle Campus, Perth, Western Australia, Australia
  5. 5Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia
  1. Correspondence to Dr Rajvi Shah; rajvishah06{at}gmail.com

Abstract

Background Ambulatory palliative care clinics are associated with improved outcomes in cancer patients, including short-term quality of life. However, their impact on individual patient-reported symptoms is not well understood.

Aim We evaluated the impact of ambulatory palliative care on individual symptoms in adult cancer patients.

Design Following a standard protocol (PROSPERO: CRD42022321909), investigators independently identified randomised and non-randomised intervention studies that assessed patient-reported symptom scores using validated symptom assessment scales longitudinally. Data were synthesised using random-effects meta-analyses.

Data sources Database of PubMed, CINAHL, EMBASE, PsycINFO and Cochrane Central was searched from inception to September 2023 for eligible studies.

Results 20 studies encompassing 4 prospective cohort studies, 1 randomised control trial and 15 retrospective studies were included. Most studies focused on cohorts with advanced cancers of mixed primary tumour type, were colocated within or linked to a tertiary cancer centre and assessed symptoms using the Edmonton Symptom Assessment Scale (ESAS). The meta-analyses confirmed evidence for improvement in pain (standardised mean difference (SMD) 0.31, 95% CI 0.18 to 0.44), anxiety (SMD 0.31, 95% CI 0.12 to 0.49), fatigue (SMD 0.31, 95% CI 0.10 to 0.51), insomnia (SMD 0.29, 95% CI 0.15 to 0.42), depression (SMD 0.25, 95% CI 0.09 to 0.40), drowsiness (SMD 0.23, 95% CI 0.11 to 0.34), well-being (SMD 0.28, 95% CI 0.12 to 0.45) and overall symptom burden (SMD 0.29, 95% CI 0.22 to 0.36). There was no evidence for improvement in nausea (SMD 0.19, 95% CI −0.02 to 0.40), dyspnoea (SMD 0.16, 95% CI 0.02 to 0.29) and appetite scores (SMD 0.14, 95% CI −0.00 to 0.29).

Conclusions Ambulatory palliative care had positive effects on multiple common symptoms. The strength of this evidence however is low, largely due to the considerable heterogeneity among included studies. Further research could determine thresholds on symptom assessment scales to guide urgency of referral, timing of follow-up and optimal multidisciplinary staff involvement.

  • Palliative Care
  • Cancer
  • Outpatients
  • Supportive care
  • Pain
  • Symptoms and symptom management

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

View Full Text

Footnotes

  • Contributors RS, NM and DK planned the study. RS conducted the searches, with RS and RE contributing to data analysis. RS and DH undertook the statistical analysis. All authors contributed to the final manuscript and are responsible for the content. RS is the guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.